New application of Carbocysteine (carboxymethyl cysteine)

Through Carbocysteine, the regulation of intestinal microbial metabolites and mucus barriers has solved the problem of side effects and insufficient applicability of existing antidepressants, and the effective prevention and treatment of depression and a more widely applicable new treatment plan are achieved.

CN118986952APending Publication Date: 2024-11-22NANYANG MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410984653.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing antidepressants may cause side effects and are not suitable for all populations, especially children, adolescents and pregnant women, and have inconsistent treatment effects on different patients, resulting in insufficient in the prevention and treatment of depression.

Method used

Carbocysteine ​​(carboxymethylcysteine) is used as a new antidepressant drug, which improves psychological state by regulating intestinal microbial metabolites, and exerts an antidepressant effect by regulating intestinal mucus barrier, and is suitable for a wider population.

Benefits of technology

Effectively prevent and treat depressive pleasure loss and despair behavior, it has good safety and applicability, and can be used as a new preventive and therapeutic drug or auxiliary product, providing a wider range of applicable populations and better therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986952A_ABST
    Figure CN118986952A_ABST
Patent Text Reader

Abstract

The invention discloses a novel application of Carbocysteine (carboxymethyl cysteine) in prevention and treatment of depression. The compound described by the invention can effectively prevent and treat the depression pleasant sensation deficiency symptom and despair behavior of mice, is a metabolite of intestinal microorganisms, plays a role by regulating the intestinal mucus barrier, and is different from the existing antidepressant drugs; meanwhile, the traditional Chinese medicine composition has been sold on the market for many years as a phlegm eliminating medicine, has better safety and wider applicability (suitable for more people, including children and the like), and is easier to be developed into a novel medicine or an auxiliary article for preventing and treating human depression.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a new use of Carbocysteine ​​(carboxymethylcysteine). Background Art

[0002] The antidepressants currently on the market are all developed based on the neurotransmitter theory of depression, including selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, norepinephrine and specific serotonin reuptake inhibitors, etc. These antidepressants may cause a variety of side effects, such as dizziness, insomnia, sexual dysfunction, weight gain, etc. Different patients respond differently to antidepressants, and not all patients will achieve ideal treatment effects. The use of some antidepressants in children, adolescents or pregnant women may be restricted.

[0003] Depression is on the rise worldwide, especially among young people and those under great work pressure. Therefore, there is a strong practical need to develop new antidepressant drugs to provide new options for the prevention and treatment of depression. Summary of the invention

[0004] The present invention aims at the above technical problems and provides a new use of Carbocysteine ​​for preventing and treating depression.

[0005] A new use of Carbocysteine ​​is to prevent and treat depression. The molecular formula of Carbocysteine ​​(carboxymethylcysteine) is: C5H9NO4S.

[0006] The structural formula of Carbocysteine ​​(carboxymethylcysteine):

[0007] Carbocysteine ​​(carboxymethyl cysteine, S-carboxymethyl-L-cysteine, English name S-Carboxymethyl-L-Cysteine). Carbocysteine ​​is used in health supplements or beverages to improve mental state.

[0008] The compounds described in the present invention can effectively prevent and treat anhedonia symptoms and despair behavior of depression in mice. The compounds described in the present invention are metabolites of intestinal microorganisms and exert their effects by regulating the intestinal mucus barrier, which is different from existing antidepressant drugs. At the same time, they have been on the market as expectorants for many years and should have better safety and wider applicability (applicable to a wider range of people, including children, etc.), and are easier to develop into new drugs or auxiliary products for preventing and treating human depression. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 Statistical analysis of some fecal non-targeted metabolomics test results; Figure 2 Carbocysteine ​​has been verified to have antidepressant effects at the animal level; Figure 3 Carbocysteine ​​regulates the colonic mucus barrierFig. DETAILED DESCRIPTION

[0010] The present invention is described in detail below in conjunction with the accompanying drawings: Hypericum perforatum is a traditional Chinese herbal medicine that is recognized to have definite antidepressant effects. When we studied the antidepressant effects of its main antidepressant ingredient, hyperforin, we found that hyperforin can increase the content of carbocysteine, a metabolite of intestinal microorganisms. Further experimental verification revealed that carbocysteine ​​has antidepressant effects.

[0011] 1. Carbocysteine ​​was discovered through fecal non-targeted metabolomics and bioinformatics methods.

[0012] A total of 14 mice were divided equally into the CRS group and the HYP group, with 7 mice in each group. The CRS group used chronic restraint stimulation to establish a depression model (restraint for 6-8 hours per day for a total of 10 days), and the HYP group was intraperitoneally injected with 0.38 mg / kg of hyperforin stable dicyclohexylammonium salt every day on the basis of chronic stimulation for ten consecutive days. After the end, the feces of the two groups of mice were collected, with 5 mice in each group, and the fecal non-targeted metabolomics test was performed. Figure 1 The following is a statistical analysis of some of the test results. Through bioinformatics analysis and correlation with previous studies, it was found that the metabolite Carbocysteine ​​related to bacterial metabolism was significantly increased in the HYP group.

[0013] Figure 1Statistical analysis of some fecal non-targeted metabolomics test results. A. Cluster heat map of total metabolites in feces of HYP group and CRS group. From the color, it can be seen that there are differences in metabolite content between the two groups; B. Compared with the CRS group, there are 249 metabolites with different contents, of which 182 are increased and 57 are decreased; C. Chemical formula and structural formula of carbocysteine; D. Compared with the CRS group, the content of carbocysteine ​​in the HYP group is significantly increased, with significant statistical difference. ** indicates P < 0.01.

[0014] 2. Verify the antidepressant effect of Carbocysteine ​​at the animal level.

[0015] 7-week-old C57bl / 6j mice were divided into three groups, CON group (8 mice), CRS group (8 mice), and Carb group (10 mice). The CON group did not receive any treatment, the CRS group was subjected to chronic restraint stimulation to establish a depression model (restraint for 2 hours per day, for a total of 14 days), and the Carb group was given Carbocysteine ​​every day for 14 days on the basis of restraint stimulation (Carbocysteine ​​was dissolved in water, and the solubility was adjusted with sodium hydroxide until it was completely dissolved, so that the pH value was between 8-9 and the concentration was 1.6 mg / ml. Based on the daily drinking water volume of 4 ml per mouse, each mouse was orally administered with about 6.4 mg of Carbocysteine. This dose was obtained by converting the dose of Carbocysteine ​​used in humans for expectoration into the dosage for animals). Behavioral tests showed that Carbocysteine ​​could prevent and treat the anhedonia symptoms of depression and the despair behavior of depression.

[0016] Figure 2 Carbocysteine ​​was verified to have antidepressant effects at the animal level. A. Experimental flow chart. 7-week-old C57bl / 6j mice were first adaptively raised for 1 week. After that, the CRS group was subjected to chronic restraint stimulation to establish a depression model (restraint for 2 hours per day for a total of 14 days). The Carb group was given Carbocysteine ​​on the basis of restraint stimulation. After the model was established, behavioral tests and tissue sampling were performed; B. Sugar water preference experiment was used to detect the anhedonia of mice. Compared with the CRS group, the mice in the Carb group were more inclined to drink sugar water, indicating that Carbocysteine ​​can prevent and treat the anhedonia symptoms of depression; C. Forced swimming experiment was used to detect the despair behavior of mice. Compared with the CRS group, the mice in the Carb group had a shorter immobility time in the experiment, indicating that Carbocysteine ​​can prevent and treat the despair behavior of depression. * indicates P < 0.05.

[0017] 3. The mechanism of carbocysteine ​​in preventing and treating depression may be to regulate the intestinal mucus barrier.

[0018] The proximal colon of the three groups of mice was dissected for histological examination to analyze the effect of carbocysteine ​​on mucus secretion of colonic goblet cells and the mucus barrier of colonic mucosa. The feces of the two groups of mice were collected to extract the supernatant, and the content of mucin2 was detected to analyze the effect of carbocysteine ​​on mucin2 secretion. It was found that compared with the CRS group, carbocysteine ​​can cause the colon to secrete more mucus and regulate the colonic mucus barrier.

[0019] Figure 3 Figure 1 shows the regulation of colon mucus barrier by carbocysteine. A. Colon PAS staining reflects the secretion of goblet cell mucus. It was found that the Carb group had more stained goblet cells and the staining was more obvious, indicating that it secreted more mucus. B. Colon scanning electron microscopy was used to observe the distribution of mucus on the luminal surface of the colon. It was found that compared with the CRS group, the mucus layer on the luminal surface of the colon in the Carb group was complete and dense; C. The ELISA method was used to detect the content of mucin2 in the fecal supernatant. It was found that the content of mucin2 in the feces of the Carb group was slightly higher than that of the other two groups, with statistical differences, indicating that carbocysteine ​​promotes the secretion of mucin2, the main mucus component in the colon. ** indicates P < 0.01, and * indicates P < 0.05.

Claims

1. A new use of Carbocysteine, characterized in that: A new use of carbocysteine ​​is to prevent and treat depression.

2. A novel use of Carbocysteine ​​as claimed in claim 1, characterized in that: The molecular formula of Carbocysteine ​​is: C5H9NO4S.

3. A novel use of Carbocysteine ​​as claimed in claim 1 or 2, characterized in that: The structural formula of the Carbocysteine ​​is:

4. A novel use of Carbocysteine ​​as claimed in claim 3, characterized in that: The Chinese name of Carbocysteine ​​is carboxymethylcysteine.

5. A drug for preventing and treating depression, characterized in that: The drugs include Carbocysteine.

6. A drug for preventing and treating depression as claimed in claim 5, characterized in that: The Chinese name of Carbocysteine ​​is carboxymethylcysteine.

7. A new use of Carbocysteine, characterized in that: Application of Carbocysteine ​​in health products.

8. A new use of Carbocysteine, characterized in that: Application of Carbocysteine ​​in beverages.